A carregar...
Novel Phenoxazinones as potent agonist of PPAR-α: design, synthesis, molecular docking and in vivo studies
BACKGROUND: The use of statin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for the treatment of dyslipidemia has been associated with dose limiting hepatoxicity, mytotoxicity and tolerability due to myalgias thereby necessitating the synthesis of new drug candidates for the treatment...
Na minha lista:
| Publicado no: | Lipids Health Dis |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5964670/ https://ncbi.nlm.nih.gov/pubmed/29789011 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12944-018-0764-y |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|